Natco Pharma Announces Consolidated Financial Results for FY2026, Reports INR 4,375.9 Crore Revenue
Natco Pharma Limited today announced its consolidated financial results for the fourth quarter and the full financial year (FY26) ended March 31, 2026. The Company reported consolidated revenues of INR 4,375.9 Crore for the year, marking a decline from INR 4,784.0 Crore recorded in the previous fiscal year.For the fourth quarter (Q4) ended March 31, 2026, Natco recorded consolidated revenue of INR 816.9 Crore, compared to INR 1,287.3 Crore during Q4 of the previous year.
The net profit for the full financial year reached INR 1,418.5 Crore, down from INR 1,883.4 Crore in FY25. For the quarter, the consolidated profit was INR 269.0 Crore, compared to INR 406.0 Crore for the corresponding period last year.
Financial Highlights
The financial results include a one-time benefit of INR 115 Crore. This adjustment is attributed to the Company's election to move to the new tax regime from the fiscal year 2026-27, resulting in the re-measurement of deferred tax assets on MAT credit and other deferred tax assets/liabilities.
The consolidated results also reflect the revenue and profit derived from the associate company, Adcock Ingram Holdings Limited, South Africa. During the quarter, revenue from the associate stood at INR 1,208.2 Crore, with a profit after tax of INR 102.5 Crore. Natco's share of the profit, based on the current holding, was INR 35.7 Crore.
Segmental Breakdown
The Company provided a segmental revenue split detailing its performance across key business areas.
| Business Segment | Q4 FY26 (INR Crore) | FY26 (INR Crore) |
|---|---|---|
| Active Pharmaceutical Ingredients (API) | 63.9 | 234.7 |
| Domestic Formulations | 108.7 | 440.9 |
| Formulations Export (Incl. profit share and subs) | 539.6 | 3,234.5 |
| Crop Health Sciences (CHS) | 22.6 | 138.2 |
| Other operating and non-operating income | 82.1 | 327.5 |
| Total | 816.9 | 4,375.9 |
The financial results for the year ended March 31, 2026, are presented on a consolidated basis, covering the parent company and its subsidiaries and associate.
Summary of Consolidated Financial Results
The following table summarizes the key financial indicators for the full financial year and the fourth quarter.
| Metric | Q4 FY26 | FY26 | Q4 FY25 | FY25 |
|---|---|---|---|---|
| Total Revenue | 816.9 Crore | 4,375.9 Crore | 1,287.3 Crore | 4,784.0 Crore |
| Profit After Tax (PAT) | 269.0 Crore | 1,418.5 Crore | 406.0 Crore | 1,883.4 Crore |
***
About Natco Pharma Limited
Natco Pharma Limited, headquartered at Hyderabad, India, develops, manufactures, and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients, and crop protection products. The Company is a research and development oriented, science-driven leader in oncology targeted therapies in the domestic market and focuses on limited competition molecules in the US. The Company's manufacturing facilities are approved by numerous global regulatory authorities.
NATCOPHARM Stock Price Movement
As of 2:48 PM, shares of Natco Pharma Limited are shedding 9.51% in live trading, currently hovering around ₹1064. The stock has seen significant movement today, with over 2.07 million shares navigating the market so far.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: